This year's J.P. Morgan Healthcare Conference wrapped up without the usual high level of M&A we've grown accustomed to.
Boston Scientific signed the only megadeal of the conference, acquiring Penumbra for $14.5bn. Meanwhile, Eli Lilly signed a $1bn partnership with Nvidia. These deals were the highlights from an unusually quiet event in San Francisco. However, there was still lots to unpack from CEO-led sessions where company strategies were laid out for upcoming years.
In the latest GlobalData Healthcare podcast, Robert Barrie, editor for Pharmaceutical Technology, and Ross Law, reporter at Medical Device Network, discuss the lacklustre deal activity from the conference, along with all the main takeaways from company presentations.
